Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | NLN | Q9BYT8 | 1/20 | 0.33 |
| ▸ | CSK | P41240 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3835499 | 1.00 | LTA4H (0.33) | LTA4HCYP3A4SLC7A5NLNCSK | |
| SCHEMBL1070087 | 0.86 | CSK (0.33) | CYP3A4SLC7A5NLNCSK | |
| SCHEMBL11620101 | 0.86 | CSK (0.45) | CYP3A4SLC7A5NLNCSK | |
| SCHEMBL4197031 | 0.86 | CSK (0.45) | CYP3A4SLC7A5NLNCSK | |
| SCHEMBL1070085 | 0.86 | CSK (0.33) | CYP3A4SLC7A5NLNCSK | |
| SCHEMBL24270549 | 0.85 | SMN1; SMN2 (0.33) | CSK | |
| SCHEMBL13270040 | 0.85 | OPRM1 (0.33) | — | |
| SCHEMBL18210638 | 0.85 | NLN (0.32) | NLNCSK | |
| SCHEMBL29616794 | 0.85 | CSK (0.33) | CSK | |
| SCHEMBL14065661 | 0.85 | SMN1; SMN2 (0.33) | CSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2101728-A1 | DISPERSION OF POLYAMINO ACIDS IN A CONTINUOUS LIPID PHASE | Flamel Technologies (FR) | 2009-09-23 | — | — | EP | claimed |
| WO-2008074871-A1 | DISPERSION OF POLYAMINO ACIDS IN A CONTINUOUS LIPID PHASE | FLAMEL TECHNOLOGIES (FR) | 2008-06-26 | — | — | WO | claimed |
| US-20080152675-A1 | Sustained release of drug in an aqueous phase containing at least one amphiphilic polymer; dispersion in a continuous lipid phase; water in oil emulsions; low viscosity for injection; aspartate-glutamate or aspartic-glutamic copolymers; biodrugs | FLAMEL TECHNOLOGIES, S.A. (FR) | 2008-06-26 | — | — | US | claimed |
| US-5409893-A | Administering with platinum complexes | BOEHRINGER MANNHEIM ITALIA, S.P.A. (IT) | 1995-04-25 | — | — | US | claimed |
| US-20230065217-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. | 2023-03-02 | — | — | US | disclosed |
| WO-2021113851-A2 | PEPTIDE DOCKING VEHICLE FOR TARGETED NUCLEIC ACID DELIVERY | SIRNAOMICS, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| US-9139614-B2 | Modular linkers for conjugation of organic substances to substantially inorganic substances and methods of manufacture and use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2015-09-22 | — | — | US | disclosed |
| US-5409893-A | Administering with platinum complexes | BOEHRINGER MANNHEIM ITALIA, S.P.A. (IT) | 1995-04-25 | — | — | US | disclosed |
| EP-0471709-B1 | RUTHENIUM(III) COMPLEXES AS ANTINEOPLASTIC AGENTS | BOEHRINGER MANNHEIM ITALIA (IT) | 1994-11-30 | — | — | EP | disclosed |
| EP-0471709-A1 | RUTHENIUM(III) COMPLEXES AS ANTINEOPLASTIC AGENTS. | BOEHRINGER MANNHEIM ITALIA (IT) | 1992-02-26 | — | — | EP | disclosed |
| WO-1990013553-A1 | RUTHENIUM(III) COMPLEXES AS ANTINEOPLASTIC AGENTS | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1990-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230065217-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | MRGPRX2, MRGPRX1, MRGPRX4 | LTA4H 2941/4885CYP3A4 3553/4885SLC7A5 2686/4885 |
| US-20080152675-A1 | Sustained release of drug in an aqueous phase containing at least one amphiphilic polymer; dispersion in a continuous lipid phase; water in oil emulsions; low viscosity for injection; aspartate-glutamate or aspartic-glutamic copolymers; biodrugs | PHOSPHO1, GLUL, GRIA1 | LTA4H 274/4885CYP3A4 2205/4885SLC7A5 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.